Life
STAT+: Neurocrine Biosciences to buy Soleno Therapeutics in $2.9B deal
Infrastructure lens: Neurocrine Biosciences is buying Soleno Therapeutics for $2.9 billion, picking up an approved medicine for a rare disease that causes insatiable hunger.
Editorial Staff
1 min read
Summary
- Primary development: STAT+: Neurocrine Biosciences to buy Soleno Therapeutics in $2.9B deal
- Coverage synthesized from 1 sources in the cluster.
- This draft should be editor-reviewed before publication.
Key Facts
| Fact | Value |
|---|---|
| Primary source | STAT |
| Source count | 1 |
| First published | 2026-04-06T11:58:02.000Z |